Cyclerion Therapeutics (NASDAQ:CYCN) Issues Quarterly Earnings Results

Cyclerion Therapeutics (NASDAQ:CYCN) released its earnings results on Tuesday. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($7.10) by $6.69, FiscalAI reports. Cyclerion Therapeutics had a negative return on equity of 62.10% and a negative net margin of 170.11%.

Cyclerion Therapeutics Stock Up 0.9%

Cyclerion Therapeutics stock traded up $0.03 during mid-day trading on Tuesday, hitting $3.52. 6,374 shares of the company’s stock were exchanged, compared to its average volume of 2,590,489. The company’s 50 day simple moving average is $3.37 and its 200-day simple moving average is $2.60. The firm has a market capitalization of $16.47 million, a P/E ratio of -2.59 and a beta of 1.76. Cyclerion Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $8.48.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Cyclerion Therapeutics presently has an average rating of “Sell”.

Institutional Trading of Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP acquired a new position in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned approximately 0.40% of Cyclerion Therapeutics as of its most recent SEC filing. 75.62% of the stock is owned by institutional investors.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.